FindTrial
Sign In

Randomised double-blind clinical trial of Onabotulinumtoxin A injection into the corpora cavernosa in patients with erectile dysfunction refractory to treatment with phosphodiesterase-5 inhibitors

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514518-10-00
Acronym
BTXDE
Enrollment
114
Registered
2024-09-20
Start date
2024-10-31
Completion date
Unknown
Last updated
2025-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction

Brief summary

Subjective perception of rigidity

Interventions

DRUGSODIUM CHLORIDE SOLUTION 0.9%
DRUGBOTULINUM TOXIN

Sponsors

Clinica Universidad De Navarra
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Subjective perception of rigidity—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026